Clinical trial
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
NCT06783270 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
- Lead sponsor
- Inge Marie Svane
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 16, 2024
- Completion date
- January 1, 2028
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
melanoma metastatic